Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 8, 2010, Pages 750-757

  Acikel, Sadik ^a   Muderrisoglu, Haldun ^b   Yildirir, Aylin ^b   Aydinalp, Alp ^b   Sade, Elif ^b   Bayraktar, Nilufer ^b   Bal, Ugur ^b   Ozin, Bulent ^b  

^a MINISTRY OF HEALTH   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

contrast induced nephropathy; coronary angiography; statin

Indexed keywords

ATORVASTATIN; CREATININE; CYSTATIN C;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTRAST INDUCED NEPHROPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HEPTANOIC ACIDS; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES;

EID: 78349312945     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32834014a4     Document Type: Article

References (35)

1. McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 2006; 98:5-13.
2. Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA, et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol 2006; 98:59-77. (Pubitemid 44292094)
3. Attallah N, Yassine L, Musial J, Yee J, Fisher K. Thepotential roleof statinsin contrast nephropathy. Clin Nephrol 2004; 62:273-278.
4. Khanal S, Attallah N,Smith DE, Kline-Rogers E,Share D, O'Donnell MJ, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005; 118:843-849.
5. Patti G, Nusca A, Chello M, Pasceri V, D'Ambrosio A, Vetrovec GW, et al. Usefulnessof statin pretreatmentto preventcontrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol 2008; 101:279-285.
6. Yoshida S, Kamihata H, Nakamura S, Senoo T, Manabe K, Motohiro M, et al. Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency. J Cardiol 2009; 54:192-198.
7. Xinwei J, Xianghua F,Jing Z, Xinshun G, Ling X, Weize F, et al. Comparison of usefulness of simvastatin 20mg versus 80mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 2009; 104:519-524.
8. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: anew prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470.
10. Bouzas-Mosquera A, Vázquez-Rodŕiguez JM, Calviño-Santos R, Vázquez-González N, Castro-Beiras A. Statin therapy and contrast-induced nephropathy after primary angioplasty. Int J Cardiol 2009; 134:430-431.
11. Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ, et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial: a randomized controlled study. Am Heart J 2008; 155:1-8.
12. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and riskof developing renal dysfunction:theatherosclerosis riskincommunitiesstudy. Kidney Int 2000; 58:293-301.
13. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, et al.Cholesteroland the riskof renal dysfunction in apparently healthymen. JAm Soc Nephrol 2003; 14:2084-2091.
14. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. Theeffect ofcholesterol-lowering and antioxidanttherapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332:488-493.
15. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005; 96:24-33.
16. John S, Schlaich M, Langenfeld M, Weihprecht H, Schmitz G, Weidinger G, et al. Increased bioavailability of nitric oxide after lipid loweringtherapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation 1998; 98:211-216.
17. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997; 95:76-82.
18. Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, et al. Pathophysiology of contrast-induced nephropathy. Am J Cardiol 2006; 98:14-20.
19. Almuti K, Rimawi R, Spevack D, Ostfeld RJ. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol 2006; 109: 7-15.
20. Vidt DG. Inflammation in renal disease. Am J Cardiol 2006; 97:20-27.
21. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20-28.
22. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352:29-38.
23. Solomon R. Radiocontrast-induced nephropathy. Semin Nephrol 1998; 18:551-557.
24. Katholi RE, Woods WT Jr, Taylor GJ, Deitrick CL, Womack KA, Katholi CR, et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis 1998; 32:64-71.
25. Heyman SN, Rosen S, Khamaisi M, Idée JM, Rosenberger C. Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. Invest Radiol 2010; 45:188-195.
26. Stief TW. Drug-induced thrombin generation. The breakthrough. Hemost Lab 2010; 3:3-5.
27. Stief TW. Thrombin generation by the nonionic contrast medium iomeprol. Hemost Lab 2010; 3:221-228.
28. Corot C, Chronos N, Sabattier V. In vitro comparison of the effects of contrast media on coagulation and platelet activation. Blood Coagul Fibrinolysis 1996; 7:602-608.
29. Heptinstall S, White A, Edwards N, Pascoe J,Sanderson HM, Fox SC, et al. Differential effects ofthree radiographic contrast media on platelet aggregation and degranulation: implicationsforclinical practice? Haematol 1998; 103:1023-1030.
30. Jones CI, Goodall AH. Differential effects of the iodinated contrast agents ioxaglate, iohexol and iodixanol on thrombus formation and fibrinolysis. Thromb Res 2003; 112:65-71.
31. Stief TW. Neutrophil granulocytes in hemostasis. Hemost Lab 2008; 1:269-289.
32. Antonopoulos AS, Antoniades C, Tousoulis D, Bakogiannis C, Demosthenous M, Psarros C, Stefanadis C. Novel therapeutic strategies targeting vascular redox in human atherosclerosis. Recent Pat Cardiovasc Drug Discov 2009; 4:76-87.
33. Stief TW, Kurz J, Doss MO, Fareed J. Singlet oxygen inactivatesfibrinogen, factor V, factor VIII, factor X, and platelet aggregation of human blood. Thromb Res 2000; 97:473-480.
34. Stief TW. The physiology and pharmacology of singlet oxygen. Med Hypotheses 2003; 60:567-572.
35. Pastuszczak M, Kotlarz A, Mostowik M, Zalewski J, Zmudka K, Undas A. Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction. Thromb Res 2010; 125:382-386.